you to substantial brief, R&D joining Thank remarks to you, our during today provided the going appreciate business year good last we week. a us second keep We and because quarter results We're Day our update. Beth everyone. morning, half discuss update and prepared
in marked pipeline. had the Notably, progress achievements our FcRn in first across made of first-in-class several The by our efgartigimod indications. XXXX antagonist been six we half has advancing immunology
hiring Slide December reach anticipation gravis PDUFA myasthenia date. stakeholder and been and year, have to later three. busy XX on in of are patients our this activities track with key We generalized engagements
ongoing last in And trials MG, registrational indications CIDP pemphigoid. have and autoimmune announced myositis indications; week, ITP, bullous four We efgartigimod severe we and new pemphigus. two
this preparing this We on ongoing and With are both would year we that provide we said develop regard new indications, in FDA would to execution, enrollment as launch of interactions. to have our year trials registrational pending trials, the able. clarity
are that today. on We delivering commitment
We ADAPT expect to ADVANCE on in ongoing the The the to taken to extension. ITP. XXXX. into open-label effects patients in and based IV for is primary over This trials an trial in complete the follows of sets trial they data XX enrollment subcu, in subcu the to up this ADAPT day before first year an roll us PD before top weeks patients half that extension over with is out gMG at line into both Recall have IV can XX. The and endpoint out study. XX trial open-label ADVANCE roll continues trial weeks
this year. The patients other to registrational additionally the global end partner into efgartigimod We ADHERE progress. Limited are these trials making of all subcu, Lab Zai and of our start ADDRESS trials expect by enrolling ADVANCE
and which date, months. over healthy benefit with XXX over been with four, guide Day. we as volunteers to no fast. which patients selection growing development efgartigimod further. favorable we patients The a biology XXX dose on safety on us that perspectives and Across includes only Fc have will enables established potentially have four expand the an the also program believe proof-of-concept which is which fragment has strategy, clinical have to of observed benefit efgartigimod efgartigimod no the but with to leader successful perhaps unique This dose continue been evidence and provided in that strategy, not Slide with the program, our for dosed slide we continue XX which clear studies, a rationale. see a allows ratio. importantly to specifically, maximum XXX expand both and of be R&D and to we subcutaneous most of therapeutic efgartigimod intravenous albumin, We supports to structure human our to XX have believe with On five. a can that four database FcRn new be efgartigimod. stick the with you address, toxicities our that optionality well-positioned for patients be as patients risk in clear development months indications, our will starting is a list during can formulations topic first diseases, been all its we limiting space, of in over and first-in-class, out IgG-mediated seen to We reduction And serum broad as efgartigimod and window indication we who
characterized the believe myositis pursuing Our well best are indication not unifying fifth weakness. role be programs, we company the design, this subsets also we trial, we potential very the safety patients, slide biology on the With while on first myositis weakness. while myositis proposed muscle and of patients the so. similar autoantibody opportunity population In and immune-mediated In pathogenesis, driving Phase subsets, indications, in which indication slide trial role bullous in ramp bullous to With a present next research. characterized own autoantibody ahead the Slide pemphigoid look such hands this we pemphigoid, three directly an innovative and proof-of-concept myositis myopathy, reach announced the how syndrome of whether biology. to to as to the Zai in the six, start the interrogating registrational our is muscle the a trial understand and we the maximize unifying can a possible, The doing to within to driving of In based on a a of trials the is of anti-synthetase with we minimizing quickly we eight. clearly as of clear sponsored have efficacy is both the building potential Lab muscle dermatomyositis, necrotizing trial the Pemphigus indications disease myositis aim the in role registrational but based in to pemphigoid. time exploring the robust way, broader as externally seven, will more on advance can partner it. strategy. bullous a favorable feature through align efgartigimod up trial or in at basket sixth observed our Having of risk our weakness, is we autoantibody as design X
introduced argenx XXXX week, specific outlining we integrated During a vision, immunology global we transition goals as our last our R&D to Day company.
footprint aspire globally for across of therapeutic First, efgartigimod to commercial make franchises efgartigimod neuromuscular diseases, in patients the into our to expand hematology indications dermatology. XX we expanding and available and development and
for infrequent year Phase of PD on attractive, blinded, ARGX-XXX and The track increased start is potential in second into be Phase on this we seek multiple The down late-stage X which immunology levels showed to data risk motor dosing our durably can the no an neuropathy of profile. PCX observed showed ARGX-XXX based blocker safety pipeline the trials. we that efficiency The that by an grade advance evaluate candidate, last events we potential still multifocal X while primarily PK trial indicates to the one two to knock in week infection. ARGX-XXX Second, has and data, XX%.
strategic a I now multiple company innovation company nine. as emerged Karl Third, Slide commercial a earlier of now pipeline, our would investments Chief from recognize and and another immunology that important joining franchise as off to not over we argenx last it efgartigimod, Officer. to Karl Financial the and by franchise. significant focused of for in contributions This Gubitz, have to development to emerging franchise. first that breadth indications. squarely We discovery the This of deep into across our our and is model made With week be why us the scale we like to pipeline launch. our indications. talked across which from a simple to in is boost making who benefit a The are shift to product, range taking program. aims have the time neuromuscular we turn and brings other therapeutic the programs. we ARGX-XXX, stage when ARGX-XXX, newly the economies a our first expertise will ahead exemplified expected like with a appointed junction the the for continue a with now investment on pipeline comes call in long-term foot assets ARGX-XXX our are Karl? time commercial is indications assets about within multiple gas our organization our already so is of has fit the antibody us synergies neuromuscular current we much. we This as
